

Homerton University Hospital NHS Foundation Trust
Hackney College
Defoe Building, Room 10
50 Hoxton Street
N1 6LP

Date 10th August 2016

Email: foi@homerton.nhs.uk

Dear Sir or Madam,

Ref: FOI 2604

Thank you for your recent Freedom of Information request regarding the treatment for Carcinoma and Melanoma at Homerton Hospital.

The Trust can provide the following information:

Please can you supply the following information?

The number of patients with NON SMALL CELL LUNG CARCINOMA (Stage IIIB/Stage IV) treated in the last 6 months with the following:

**Afatinib (Giotrif)
Ceritinib (Zykadia)
Crizotinib (Xalkori)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Pemetrexed (Alimta)
Nivolumab (Opdivo)
Nintedanib (Vargatef)**

The Trust has treated 9 patients with Non-small cell lung carcinoma in the last 6 months on Erlotinib (Tarceva). The Trust does not provide the other medications mentioned above for treatment.

The number of patients with METASTATIC MELANOMA Stage IV (advanced or metastatic), treated in the last 6 months with the following:

**Ipilimumab (Yervoy)
Nivolumab (Opdivo)
Ipilimumab AND Nivolumab
Pembrolizumab (Keytruda)
Vemurafenib (Zelboraf)
Vemurafenib AND Cobimetinib
Dabrafenib (Tafinlar)
Trametinib (Mekinist)
Dabrafenib AND trametinib
Dacarbazine (DTIC)**

The Trust does not provide/use the medications mentioned above for treatment.

If you have any queries about this response please contact the information governance manager at foi@homerton.nhs.uk , in the first instance. If following that, you still have any concerns, you may contact the Information Commissioner either by letter, FOI/EIR Complaints resolution, Wycliffe House, Water Lane, Wilmslow, Cheshire SM9 5AF, or by email www.informationcommissioner.gov.uk to take them further.

Copyright Statement

The material provided is subject to the HUHFT's copyright unless otherwise indicated. Unless expressly indicated on the material to the contrary, it may be reproduced free of charge in any format or medium, provided it is reproduced accurately and not used in a misleading manner. Where any of the copyright items are being re-published or copied to others, you must identify the source of the material and acknowledge the copyright status. Permission to reproduce material does not extend to any material accessed through the Publication Scheme that is the copyright of third parties. You must obtain authorisation to reproduce such material from the copyright holders concerned.

Yours sincerely

Mohamed Uddin
FoI Administrator

Mike Dunne
Information Governance Manager